An observational study in HIV Infection and MDR-TB, sponsored by Zahedan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Zahedan University of Medical Sciences · Observational
This study aims to investigate the relationship between HIV infection and multi-drug resistant tuberculosis (MDR-TB) among affected individuals in Zahedan, Iran. It will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. The findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
This study's enrollment of 222,128 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Browse HIV Infections studies →Zahedan University of Medical Sciences is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult individuals (aged 18 years and older) diagnosed with both HIV infection and multi-drug-resistant tuberculosis (MDR-TB). This meta-analysis synthesizes data from various studies conducted across multiple countries, including Brazil, the USA, Canada, India, Ethiopia, and several others. The population includes a diverse cohort of patients, reflecting various demographic characteristics such as age, sex, and geographical location.
The studies included in this meta-analysis feature participants with confirmed diagnoses of HIV and MDR-TB, with a focus on understanding the co-infection dynamics, treatment outcomes, and associated health challenges. Data extraction from these studies provides insight into the prevalence and impact of MDR-TB among HIV-positive patients, highlighting the importance of tailored
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This meta-analysis examines the impact of HIV infection on the prevalence and outcomes of multi-drug resistant tuberculosis (MDR-TB) among affected populations. The analysis synthesizes data from multiple studies conducted across various countries, focusing on the correlation between HIV co-infection and MDR-TB rates, treatment outcomes, and demographic factors. The findings aim to enhance understanding of the complex interactions between HIV and MDR-TB, ultimately informing clinical practices and public health strategies.
Prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB) in HIV-Positive Patients
This study aims to determine the prevalence of multi-drug resistant tuberculosis (MDR-TB) among patients co-infected with HIV. Data will be collected from various studies included in the meta-analysis, focusing on the incidence rates of MDR-TB in this population. The analysis will provide insights into the challenges faced in treating HIV-positive individuals with MDR-TB and highlight the need for targeted interventions.
Time frame: Data collected over the course of the studies from 2006 to 2018.
Ran from May 2024 to primary completion in Aug 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zahedan University of Medical Sciences